TNFRSF4 and cancer: Given that Foxp3+ Treg cells are among the highest expressers of OX40, it is possible that PDOX treatment may also additionally benefit from the ability of OX40 antibodies to trigger Treg depletion in the TME, as has been reported in some experimental cancer models.9